PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research

Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Mou, Guang-Ze, Li, Tian-Zhu, Xu, Wan-Ting, Zhang, Tong, Xue, Hui, Zuo, Wen-Bo, Li, Yan-Nan, Luo, Ying-Hua, Jin, Cheng-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093614/
https://www.ncbi.nlm.nih.gov/pubmed/33759637
http://dx.doi.org/10.1177/15330338211004942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093614/
https://www.ncbi.nlm.nih.gov/pubmed/33759637
http://dx.doi.org/10.1177/15330338211004942

Ejemplares similares